Category Archives: – Pharma

The new CDC guidelines for prescribing opioid pain pills

June 1, 2016- Interviewed by Steven E. Greer, MD Pain pill prescriptions have quadrupled since the 1990’s as drug companies stepped up marketing and funded

Posted in - JAMA, - NEJM, - Pharma, CDC, Emergency medicine, General surgery, Oncology, Psychology Psychiatry, Rehab, Spine surgery, Sports medicine | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr.  Ribas last year.

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Essay: Opioids coming through the Mexican border are a national security risk

Update January 8, 2019- President Trump quoted from this story tonight during his talk from the Ova

Posted in - Opinion, - Pharma, - Policy, CDC, Congress, FDA, NIH, Primary care medicine, Rehab | Leave a comment

Triple Therapy for Cystic Fibrosis

October 18, 2018- interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, FDA, Genetics, Infectious disease, Internal Medicine, National Jewish Health, Pediatrics, Pulmonology | Leave a comment

TV Quack Dr. David Agus still likes daily aspirin despite heart guidelines dropping it

March 23, 2019

Posted in - Pharma, Cardiology, CDC, FDA, Oncology | Comments Off on TV Quack Dr. David Agus still likes daily aspirin despite heart guidelines dropping it

Daily aspirin once again proves to be of no use and also deadly

Update January 13, 2015- Yet another study was published highlighting the risks of daily aspirin. 

Posted in - JAMA, - Pharma, - Policy, Cardiac surgery, Cardiology, Gastroenterology and liver, General surgery, Neurology, Neurosurgery, Oncology, Primary care medicine | Leave a comment

President-elect Trump adopts plan by The Healthcare Channel to bring back drug manufacturing jobs

September 4, 2010- by Steven Greer, MD The Commissioner of the FDA, Margaret Hamburg, could become the single biggest job creator

Posted in - Opinion, - Pharma, - Policy, CMS, Congress, FDA | Leave a comment

Once again, daily aspirin is shown to be deadly rather than beneficial

September 16, 2018- by Steven E. Greer, MD The Healthcare Channel has been pounding the table for many years pushing back against the drug

Posted in - NEJM, - Pharma, Cardiac surgery, Cardiology, Gastroenterology and liver, Geriatrics, Internal Medicine, Neurology, Neurosurgery, Oncology, Vascular Surgery | Leave a comment

Industry conflicts arise at PCORI threatening any real comparative effectiveness research

February 7, 2014- By Steven E. Greer, MD The Patient Centered Outcome Research Institute (PCORI) was created by the PPACA “ObamaCare” law in 2010.

Posted in - Medical Devices, - Opinion, - Pharma, CMS, Congress, Yale | Leave a comment

Review of immunotherapy and targeted therapy

June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Year in Review: 2018

December 29, 2018- by Steven E. Greer, MD The biggest stories this year related

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

Insurance companies are not paying for Repatha and Praluent

Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

Steven E. Greer, MD, on CNBC discussing antidepressants

June 8, 2018– In the news recently are the suicide deaths of Kate Spade and Anthony Bourdain.

Posted in - Pharma, FDA, Psychology Psychiatry | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways

March 19, 2013- Interviewed by Steven E. Greer, MD The upcoming ASCO meeting will be dominated by numerous presentations relating to new

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Why are suicide rates increasing along with increased usage of antidepressants?

June 8, 2018- Fox News’ Tucker Carlson interviewed author Johan Hari about his book Lost Connections and the

Posted in - Pharma, - Policy, CDC, FDA, Neurology, Primary care medicine, Psychology Psychiatry | Leave a comment

“You’re telling me this now?” Why the news is suddenly critical of statins and antidepressants

Opinion: February 19, 2012  By Steven Greer, MD The CBS news show “60 Minutes” made waves with a story asserting that the antidepressants

Posted in - Opinion, - Pharma, - Policy, Congress, FDA | Leave a comment

FDA CDER Director on Benlysta for lupus and adaptive clinical trials.

July 27, 2011- Janet Woodcock, MD, Director of the FDAs new drug division, CDER, discusses with Steven Greer,

Posted in - Biotech, - Pharma, FDA, Rheumatology | Leave a comment